IJGPNInternational Journal of General Practice Nursing2981-94152981-9423Bio-Byword Scientific Publishing Pty. Ltd.10.26689/ijgpn.v3i4.12641ArticleFirsekibart in Reducing High-Sensitivity C-reactive Protein Levels of Gouthttps://artdesignp.com/journal/IJGPN/3/4/10.26689/ijgpn.v3i4.12641XueYu,LiYi,LianYuling,GuFei,ChenChunxia,XuQian2025342025-11-07Background: Gout remains a challenging condition with rising global prevalence. The IL-1β drives disease pathogenesis, and high-sensitivity C-reactive protein (hsCRP) correlates with gout activity. Firsekibart, a novel fully human anti-IL-1β monoclonal antibody, has proven its efficacy on gout, while the data on reducing hsCRP remains limited. Methods: This multicenter, randomized, double-blind phase III trial compared Firsekibart (200 mg subcutaneous) with compound betamethasone (7 mg intramuscular) in acute gout patients who were contraindicated to, intolerant of, or unresponsive to NSAIDs and/or colchicine. Serum hsCRP levels were measured at 72 hours, 7 days post-dose, and 4 weeks post-dose. Results: Both groups achieved comparable hsCRP reduction at 72 hours (Firsekibart: −14.68 mg/L [95% CI: −15.75, −13.61] vs. compound betamethasone: −14.58 mg/L [−15.66, −13.50]; P=0.898). Firsekibart demonstrated better sustained suppression at 7 days post-dose (−18.63 vs. −9.28 mg/L, P<0.001) and 4 weeks (−18.37 vs. −12.65 mg/L, P<0.0001). Conclusion: Compared with compound betamethasone, Firsekibart showed a longer-lasting anti-inflammatory effect on gout patients. This result may provide significant clinical value in the management of gout and its associated complications.

Punzi L, Scagnellato L, Galozzi P, et al., 2025, Gout: One Year in Review 2025. Clinical and Experimental Rheumatology, 43(5): 799–808.

Asghari KM, Zahmatyar M, Seyedi F, et al., 2024, Gout: Global Epidemiology, Risk Factors, Comorbidities and Complications: A Narrative Review. BMC Musculoskeletal Disorders, 25(1): 1047.

Yu W, Cheng JD, 2020, Uric Acid and Cardiovascular Disease: An Update from Molecular Mechanism to Clinical Perspective. Frontiers in pharmacology, 2020(11): 582680.

Dehlin M, Jacobsson L, Roddy E, 2020, Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors. Nature Reviews: Rheumatology, 16(7): 380–390.

Liu J, Liu G, Chu T, et al., 2025, The Progress of Immune Cells-induced Inflammatory Response in Gout. Current Pharmaceutical Design, advance online publication.

Yang G, Kang HC, Cho YY, et al., 2022, Inflammasomes and their Roles in Arthritic Disease Pathogenesis. Frontiers in Molecular Biosciences, 2022(9): 1027917.

Zhuang Y, Pan B, Zhang Y, et al., 2024, Structure-activity Relationships of Natural and Synthetic Lathyrane-based Diterpenoids for Suppression of NLRP3-driven Inflammation and Gouty Arthritis. Bioorganic Chemistry, 2024(150): 107558.

Ridker PM, Hennekens CH, Buring JE, 2000, C-reactive Protein and other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. The New England Journal of Medicine, 342(12): 836–843.

Meng J, Li Y, Yuan X, et al., 2017, Effects of febuxostat on Insulin Resistance and Expression of High-sensitivity C-reactive Protein in Patients with Primary Gout. Rheumatology international, 37(2): 299–303.

Santas E, Villar S, Palau P, et al., 2024, High-sensitivity C-reactive Protein and Risk of Clinical Outcomes in Patients with Acute Heart Failure. Scientific Reports, 14(1): 21672.

Tan H, Zhang S, Liao J, et al., 2024, Mechanism of Macrophages in Gout: Recent Progress and Perspective. Heliyon, 10(19): e38288.

Ridker PM, Everett BM, Thuren T, et al., 2017, Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 377(12): 1119–1131.

Terkeltaub RA, Schumacher HR, Carter JD, et al., 2013, Rilonacept in the Treatment of Acute Gouty Arthritis: A Randomized, Controlled Clinical Trial using Indomethacin as the Active Comparator. Arthritis Research & Therapy, 15(1): R25.

So A, De Smedt T, Revaz S, et al., 2007, A Pilot Study of IL-1 Inhibition by Anakinra in Acute Gout. Arthritis Research & Therapy, 9(2): R28.

Schlesinger N, Pillinger MH, Simon LS, et al., 2023, Interleukin-1β Inhibitors for the Management of Acute Gout Flares: A Systematic Literature Review. Arthritis Research & Therapy, 25(1): 128.

Schlesinger, N, Pillinger MH, Simon LS, et al., 2023, Interleukin-1β Inhibitors for the Management of Acute Gout Flares: A Systematic Literature Review. Arthritis Research & Therapy, 25(1): 128.

FitzGerald JD, Dalbeth N, Mikuls T, et al., 2020, 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6): 744–760.

Xue Y, Chu T, Hu J, et al., 2025, Firsekibart Versus Compound Betamethasone in Acute Gout Patients Unsuitable for Standard Therapy: A Randomized Phase 3 Trial. Innovation (Cambridge (Mass.)), 6(8): 101015.

Guo Q, Jin Y, Chen X, et al., 2024, NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications. Signal Transduction and Targeted Therapy, 9(1): 53.

Tan H, Zhang S, Zhang Z, et al., 2024, Neutrophil Extracellular Traps Promote M1 Macrophage Polarization in Gouty Inflammation via Targeting Hexokinase-2. Free Radical Biology & Medicine, 2024(224): 540–553.

Gao F, Peng H, Gou R, et al., 2025, Exploring Neutrophil Extracellular Traps: Mechanisms of Immune Regulation and Future Therapeutic Potential. Experimental Hematology & Oncology, 14(1): 80.

Mitroulis I, Kambas K, Chrysanthopoulou A, et al., 2011, Neutrophil Extracellular Trap Formation is Associated with IL-1β and Autophagy-related Signaling in Gout. PloS One, 6(12): e29318.

Wijdan SA, Nasir Abbas Bokhari SM, Alvares J, et al., 2025, The Role of Interleukin-1 Beta in Inflammation and the Potential of Immune-targeted Therapies. Pharmacological Research-Reports, 2025(3): 100027.

de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al., 2013, Sustained Efficacy of the Monoclonal anti-interleukin-1 Beta Antibody Canakinumab in a 9-month Trial in Schnitzler’s Syndrome. Annals of the Rheumatic Diseases, 72(10): 1634–1638.

Richette P, Doherty M, Pascual E, et al., 2017, 2016 Updated EULAR Evidence-based Recommendations for the Management of Gout. Annals of the Rheumatic Diseases, 76(1): 29–42.

Schlesinger N, Alten RE, Bardin T, et al., 2012, Canakinumab for Acute Gouty Arthritis in Patients with Limited Treatment Options: Results from two Randomised, Multicentre, Active-controlled, Double-blind Trials and their Initial Extensions. Annals of the Rheumatic Diseases, 71(11): 1839–1848.

Imazio M, Lazaros G, Gattorno M, et al., 2022, Anti-interleukin-1 Agents for Pericarditis: A Primer for Cardiologists. European Heart Journal, 43(31): 2946–2957.

Schlesinger N, Mysler E, Lin HY, et al., 2011, Canakinumab Reduces the Risk of Acute Gouty Arthritis Flares during Initiation of Allopurinol Treatment: Results of a Double-blind, Randomised Study. Annals of the Rheumatic Diseases, 70(7): 1264–1271.

Kong N, Xue Y, Mao L, et al., 2025, Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial. Rheumatology and Therapy, advance online publication. https://doi.org/10.1007/s40744-025-00790-6

Li Y, Zhang Y, Lu J, et al., 2021, Anti-inflammatory Mechanisms and Research Progress of Colchicine in Atherosclerotic Therapy. Journal of Cellular and Molecular Medicine, 25(17): 8087–8094.

Tan Q, Yang ZM, Chen W, et al., Trends and Development in Clinical Research of FDA-Approved Drugs Against Interleukin-1β: A Bibliometric Analysis. Preprint.